Normocalcemic primary hyperparathyroidism in patients with recurrent kidney stones: Pathological analysis of parathyroid glands

Virchows Archiv

Volumn 449, Issue 1, 2006, Pages 62-68

  Yang, An Hang ^a,b   Hsu, Chih Wei ^a   Chen, Jui Yu ^a   Tseng, Ling Ming ^a   Won, Ging Shing ^a,b   Lee, Chen Hsen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Hyperparathyroidism; Immunohistochemistry; Nephrolithiasis; Normocalcemia

Indexed keywords

CALCIUM; CALCIUM SENSING RECEPTOR; CHROMOGRANIN A; CYCLIN D1; KI 67 ANTIGEN; PARATHYROID HORMONE; VITAMIN D RECEPTOR;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; FEMALE; HUMAN; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PARATHYROID ADENOMA; PARATHYROID CELL; PARATHYROID GLAND; PARATHYROID HYPERPLASIA; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RECURRENT DISEASE; TISSUE MICROARRAY;

CALCIUM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; HYPERCALCEMIA; HYPERPLASIA; HYPERTHYROIDISM; KIDNEY CALCULI; MALE; MIDDLE AGED; PARATHYROID GLANDS; RECURRENCE; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 33745616065     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-006-0222-5     Document Type: Article

References (34)

1. Canaff L, Hendy GN (2002) Human calcium-sensing receptor gene. Vitamin D response elements in promoter P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 277:30337-30350
2. Chattopadhyay N (2000) Biochemistry, physiology and pathophysiology of the extracellular calcium-sensing receptor. Int J Biochem Cell Biol 32:789-804
3. Cohn DV, Fasciotto BH, Reese BK, Zhang JX (1995) Chromogranin A: a novel regulator of parathyroid gland secretion. J Nutr 125:2015S-2019S
4. Correa P, Akerstrom G, Westin G (2002) Exclusive underexpression of vitamin D receptor exon 1f transcripts in tumors of primary hyperparathyroidism. Eur J Endocrinol 147:671-675
5. Farnebo F, Hoog A, Sandelin K, Larsson C, Farnebo LO (1998) Decreased expression of calcium-sensing receptor messenger ribonucleic acids in parathyroid adenomas. Surgery 124:1094-1098
6. Fasciotto BH, Trauss CA, Greeley GH, Cohn DV (1993) Parastatin (porcine chromogranin A347-419), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion. Endocrinology 133:461-466
7. Fasciotto BH, Denny JC, Greeley GH Jr, Cohn DV (2000) Processing of chromogranin A in the parathyroid: generation of parastatin-related peptides. Peptides 21:1389-1401
8. Gardin JP, Paillard M (1984) Normocalcemic primary hyperparathyroidism: resistance to PTH effect on tubular reabsorption of calcium. Miner Electrolyte Metab 10:301-308
9. Garfia B, Canadillas S, Canalejo A, Luque F, Siendones E, Quesada M, Almaden Y, Aguilera-Tejero E, Rodriguez M (2002) Regulation of parathyroid vitamin D receptor expression by extracellular calcium. J Am Soc Nephrol 13:2945-2952
10. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drueke TB (1997) Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51:328-336
11. Grimelius L, Johansson H, Lindquist B, Thoren L, Werner I (1973) Normocalcemic primary hyperparathyroidism. Acta Chir Scand 139:42-44
12. Hagag P, Revet-Zak I, Hod N, Horne T, Rapoport MJ, Weiss M (2003) Diagnosis of normocalcemic hyperparathyroidism by oral calcium loading test. J Endocrinol Invest 26:327-332
13. Imanishi Y, Hosokawa Y, Yoshimoto K, Schipani E, Mallya S, Papanikolaou A, Kifor O, Tokura T, Sablosky M, Ledgard F, Gronowicz G, Wang TC, Schmidt EV, HallC, Brown EM, Bronson R, Arnold A (2001) Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 107:1093-1102
14. Johansson H, Thoren L, Werner I, Grimelius L (1975) Normocalcemic hyperparathyroidism, kidney stones, and idiopathic hypercalciuria. Surgery 77:691-696
15. Kifor O, Moore FD Jr, Wang P, Goldstein M, Vassilev P, Kifor I, Hebert SC, Brown EM (1996) Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81:1598-1606
16. Levine MA, Dempsey MA, Helman LJ, Ahn TG (1990) Expression of chromogranin-A messenger ribonucleic acid in parathyroid tissue from patients with primary hyperparathyroidism. J Clin Endocrinol Metab 70:1668-1673
17. Lundgren E, Ridefelt P, Akerstrom G, Ljunghall S, Rastad J (1996) Parathyroid tissue in normocalcemic and hypercalcemic primary hyperparathyroidism recruited by health screening. World J Surg 20:727-734
18. Luong KV, Nguyen LT (2000) Normocalcemic hyperparathyroidism in Vietnamese immigrants living in southern California. Am J Med Sci 319:380-384
19. Maruani G, Hertig A, Paillard M, Houillier P (2003) Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88:4641-4648
20. Monchik JM (1995) Normocalcemic hyperparathyroidism. Surgery 118:917-923
21. Poole GV Jr, Albertson DA, Myers RT (1983) Normocalcemic hyperparathyroidism revisited. Am Surg 49:668-671
22. Russell J, Gee P, Liu SM, Angeletti RH (1994) Inhibition of parathyroid hormone secretion by amino-terminal chromogranin peptides. Endocrinology 135:337-342
23. Schmid KW, Hittmair A, Ladurner D, Sandbichler P, Gasser R, Totsch M (1991) Chromogranin A and B in parathyroid tissue of cases of primary hyperparathyroidism: an immunohistochemical study. Virchows Arch A Pathol Anat Histopathol 418:295-299
24. Shieber W, Birge SJ, Avioli LV, Teitelbaum SL (1971) Normocalcemic hyperparathyroidism with "normal" parathyroid glands. Arch Surg 103:299-302
25. Silverberg SJ, Bilezikian JP (2003) "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab 88:5348-5352
26. Siminovitch JM, James RE, Esselstyn CB Jr, Straffon RA, Banowsky LH (1980) The effect of parathyroidectomy in patients with normocalcemic calcium stones. J Urol 123:335-337
27. Siperstein AE, Shen W, Chan AK, Duh QY, Clark OH (1992) Normocalcemic hyperparathyroidism. Biochemical and symptom profiles before and after surgery. Arch Surg 127:1157-1160
28. Tanaka R, Umemura S, Kakuta T, Fujisaki T, Sakai H, Saitoh A, Osamura RY (2003) Co-expression of parathyroid hormone and chromogranin A in secondary hyperparathyroidism: a functional marker for secretory activity of hyperplastic nodules. Pathol Res Pract 199:93-99
29. Weber CJ, Russell J, Chryssochoos JT, Hagler M, McGarity WC (1996) Parathyroid hormone content distinguishes true normal parathyroids from parathyroids of patients with primary hyperparathyroidism. World J Surg 20:1010-1014
30. Wills MR, Pak CY, Hammond WG, Bartter FC (1969) Normocalcemic primary hyperparathyroidism. Am J Med 47:384-391
31. Wu PH, Wang CJ (2002) Normocalcemic primary hyperparathyroidism with fractures. J Arthroplasty 17:805-809
32. Yano S, Sugimoto T, Tsukamoto T, Chihara K, Kobayashi A, Kitazawa S, Maeda S, Kitazawa R (2000) Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int 58:1980-1986
33. Yong JL, Vrga L, Warren BA (1994) A study of parathyroid hyperplasia in chronic renal failure. Pathology 26:99-109
34. Zhang JX, Fasciotto BH, Darling DS, Cohn DV (1994) Pancreastatin, a chromogranin A-derived peptide, inhibits transcription of the parathyroid hormone and chromogranin A genes and decreases the stability of the respective messenger ribonucleic acids in parathyroid cells in culture. Endocrinology 134:1310-1316